Two Sigma Advisers’s GSK GSK Stock Holding History

Two Sigma Advisers’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-21,120	Closed	-$813K	–	2373
2024 Q2	$813K	Buy	+21,120	New	+$888K	﹤0.01%	1659
2023 Q2	–	Sell	-172,692	Closed	-$6.14M	–	2494
2023 Q1	$6.14M	Sell	172,692 -2,019,600	-92%	-$70.7M	0.02%	728
2022 Q4	$77M	Sell	2,192,292 -2,319,120	-51%	-$77.2M	0.22%	103
2022 Q3	$133M	Buy	4,511,412 +4,185,599	+1,285%	+$159M	0.38%	56
2022 Q2	$17.7M	Buy	+325,813	New	+$18M	0.05%	349
2022 Q1	–	Sell	-723,813	Closed	-$39.9M	–	2796
2021 Q4	$39.9M	Sell	723,813 -1,934,080	-73%	-$101M	0.1%	183
2021 Q3	$127M	Buy	2,657,893 +2,609,680	+5,413%	+$131M	0.33%	70
2021 Q2	$2.4M	Sell	48,213 -566,240	-92%	-$27.2M	0.01%	1209
2021 Q1	$27.4M	Buy	614,453 +517,760	+535%	+$23.5M	0.08%	280
2020 Q4	$4.45M	Sell	96,693 -1,348,320	-93%	-$61.9M	0.01%	870
2020 Q3	$68M	Sell	1,445,013 -544,400	-27%	-$27.3M	0.19%	119
2020 Q2	$101M	Buy	1,989,413 +1,621,360	+441%	+$83.2M	0.3%	74
2020 Q1	$17.4M	Buy	368,053 +336,613	+1,071%	+$18M	0.07%	317
2019 Q4	$1.85M	Sell	31,440 -329,733	-91%	-$18.3M	﹤0.01%	1267
2019 Q3	$19.3M	Buy	361,173 +56,800	+19%	+$2.92M	0.05%	382
2019 Q2	$15.2M	Sell	304,373 -252,320	-45%	-$12.7M	0.04%	469
2019 Q1	$29.1M	Buy	556,693 +33,920	+6%	+$1.69M	0.07%	319
2018 Q4	$25M	Sell	522,773 -2,587	-0.5%	-$127K	0.07%	328
2018 Q3	$26.4M	Sell	525,360 -272,434	-34%	-$13.8M	0.06%	320
2018 Q2	$40.2M	Sell	797,794 -1,013,040	-56%	-$51M	0.11%	232
2018 Q1	$88.4M	Sell	1,810,834 -2,248,880	-55%	-$105M	0.24%	116
2017 Q4	$180M	Buy	4,059,714 +1,449,120	+56%	+$66.9M	0.49%	37
2017 Q3	$132M	Buy	2,610,594 +416,240	+19%	+$21.1M	0.38%	60
2017 Q2	$118M	Buy	2,194,354 +295,360	+16%	+$15.7M	0.39%	55
2017 Q1	$100M	Sell	1,898,994 -56,000	-3%	-$2.84M	0.33%	67
2016 Q4	$94.1M	Buy	1,954,994 +1,824,080	+1,393%	+$90.1M	0.36%	65
2016 Q3	$7.06M	Buy	130,914 +115,234	+735%	+$6.32M	0.03%	525
2016 Q2	$849K	Sell	15,680 -67,440	-81%	-$3.55M	﹤0.01%	1247
2016 Q1	$4.21M	Buy	+83,120	New	+$4.14M	0.02%	560
2015 Q4	–	Sell	-255,893	Closed	-$12.3M	–	1919
2015 Q3	$12.3M	Sell	255,893 -404,541	-61%	-$21.1M	0.08%	295
2015 Q2	$34.4M	Buy	660,434 +335,136	+103%	+$18.9M	0.26%	102
2015 Q1	$18.8M	Sell	325,298 -247,440	-43%	-$14.2M	0.14%	190
2014 Q4	$30.6M	Sell	572,738 -504,000	-47%	-$28.2M	0.24%	95
2014 Q3	$61.9M	Buy	1,076,738 +342,880	+47%	+$21M	0.47%	40
2014 Q2	$49.1M	Buy	733,858 +105,040	+17%	+$7.11M	0.38%	49
2014 Q1	$42M	Buy	628,818 +361,200	+135%	+$24.4M	0.38%	49
2013 Q4	$17.9M	Buy	267,618 +125,360	+88%	+$8.13M	0.17%	126
2013 Q3	$8.92M	Buy	142,258 +11,706	+9%	+$754K	0.11%	216
2013 Q2	$8.16M	Buy	+130,552	New	+$8.29M	0.12%	164

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's GSK Position: Q3 2024 in Review

Two Sigma Advisers sold out of GSK (GSK) in Q3 2024, closing a stake of 21,120 shares — an estimated $813K sold.

Two Sigma Advisers first reported a position in GSK in Q2 2013 and held it in 39 quarters. The position peaked at $180M in Q4 2017. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Two Sigma Advisers reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
Two Sigma Advisers sold 21,120 GSK shares in Q3 2024, an estimated $813K.
Two Sigma Advisers first reported a position in GSK in Q2 2013 and held it in 39 quarters.
Two Sigma Advisers's GSK position peaked at $180M in Q4 2017.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Two Sigma Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.